Company: AEMD
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001683168-25-008271
Chunk: 5

Company: AETHLON MEDICAL INC
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 1
Chunk 5
---
     309  
     –  
     (3,832) 
     –  
     –  
     (3,832)
  
    Stock-based compensation expense 
     –  
     –  
     113,493  
     –  
     –  
     113,493 
  
    Net loss 
     –  
     –  
     –  
     (2,806,973) 
     –  
     (2,806,973)
  
    Other comprehensive income (loss) 
     –  
     –  
     –  
     –  
     3,804  
     3,804 
  
    BALANCE – SEPTEMBER 30, 2024 
     174,529  
    $174  
    $165,968,044  
    $(159,945,141) 
    $(3,969) 
    $6,019,108 

The accompanying notes are an integral part
of these condensed consolidated financial statements.

 6 

AETHLON MEDICAL, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Six Months Ended September 30, 2025 and
2024

(Unaudited)

    Six months  Ended  September 30, 2025  
    Six months  Ended  September 30, 2024 

    Cash flows used in operating activities: 

    Net loss 
    $(3,248,958) 
    $(5,378,414)
  
    Adjustments to reconcile net loss to net cash used in operating activities: 

    Depreciation and amortization 
     162,503  
     171,887 
  
    Stock based compensation 
     144,884  
     252,821 
  
    Amortization of right-of-use operating lease asset 
     145,350  
     139,060 
  
    Changes in operating assets and liabilities: 

    Prepaid expenses and other current assets 
     81,457  
     292,071 
  
    Accounts payable and other current liabilities 
     (327,779) 
     95,370 
  
    Due to related parties 
     (331,111) 
     465,